Delivery Order SPE2DB20D3103-SPE2DB25FP8N5
- Not listed
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $35,073.98 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 30, 2025, with performance completion due July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and...
- The Defense Logistics Agency awarded a $18,491.04 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This competitively awarded, firm fixed-price contract is a non-set-aside procurement with an ultimate completion date of August 18, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and...
- The Defense Logistics Agency awarded a delivery order valued at $12.3K to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 13, 2025, with completion targeted for August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a prescription medication used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.86 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency Medical Supply Chain awarded a $147,324.85 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This non-set-aside competitive award represents a child delivery order executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,494.79 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (UU 28s) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. RINVOQ ER is a prescription medication used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,383.94 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with a completion deadline of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a $12,446.64 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a prescription medication used to treat rheumatoid arthritis and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,525.88 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP8N5Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $60.3K to AmerisourceBergen Drug Corp for RINVOQ ER 45 MG tablets (UU 28S) with an ultimate completion date of August 13, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, representing a specialty pharmaceutical product within the company's broader federal medical supply portfolio. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9M prime vendor agreement running through December 2026 that serves as the primary pharmaceutical supply vehicle for military healthcare worldwide. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen Drug Corp supplies an extensive range of medications, vaccines, and medical supplies to support Defense Health Agency operations and other government healthcare systems. The company's consistent receipt of competitively awarded delivery orders demonstrates its established capability to meet federal procurement requirements for specialized pharmaceutical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $60.3k | 8/12/25 |